Recent Research Analysts’ Ratings Updates for Medtronic (MDT)

Medtronic (NYSE: MDT) recently received a number of ratings updates from brokerages and research firms:

• 10/6/2026 – Medtronic is now covered by Barclays PLC. They set a “positive” rating on the stock.
• 10/3/2026 – Medtronic was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/30/2026 – Medtronic had its “buy” rating reaffirmed by TD Cowen. They now have a $110.00 price target on the stock.
• 9/17/2026 – Medtronic had its “buy” rating reaffirmed by Needham & Company LLC.
• 9/5/2026 – Medtronic was downgraded by Wall Street Zen from “buy” to “hold”.
• 9/4/2026 – Medtronic was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
• 9/3/2026 – Medtronic had its “hold” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $92.00 price target on the stock.
• 9/3/2026 – Medtronic had its price target raised by UBS Group AG from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 9/2/2026 – Medtronic was given a new $115.00 price target by Mizuho.
• 9/2/2026 – Medtronic had its price target raised by Bank of America Corporation from $95.00 to $110.00. They now have a “buy” rating on the stock.
• 9/2/2026 – Medtronic had its price target raised by Wells Fargo & Company from $102.00 to $104.00. They now have an “overweight” rating on the stock.
• 9/2/2026 – Medtronic had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $99.00 price target on the stock, up from $86.00.
• 9/2/2026 – Medtronic had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $118.00 price target on the stock.
• 9/2/2026 – Medtronic had its price target raised by Robert W. Baird from $91.00 to $100.00. They now have a “neutral” rating on the stock.
• 9/2/2026 – Medtronic had its price target raised by Stifel Nicolaus from $80.00 to $95.00. They now have a “hold” rating on the stock.
• 9/1/2026 – Medtronic had its price target raised by BTIG Research from $91.00 to $100.00. They now have a “buy” rating on the stock.
• 8/28/2026 – Medtronic had its price target raised by TD Cowen from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 8/27/2026 – Medtronic had its price target raised by Needham & Company LLC from $101.00 to $114.00. They now have a “buy” rating on the stock.
• 8/18/2026 – Medtronic had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 8/18/2026 – Medtronic had its “buy” rating reaffirmed by BTIG Research. They now have a $91.00 price target on the stock.
• 8/10/2026 – Medtronic had its “neutral” rating reaffirmed by Piper Sandler.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.3%. Medtronic’s dividend payout ratio is currently 70.94%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. This trade represents a 3.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.27% of the stock is currently owned by corporate insiders.

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company’s portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.